Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: early trial of ALPS12 begins

NCT ID NCT07107490

Recruiting now Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Nov 25, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This early-phase study tests a new drug called ALPS12 in about 122 people with extensive-stage small cell lung cancer that has returned after at least one prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive ALPS12 and be closely monitored for side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ehime University Hospital

    RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • Kindai University Hospital

    RECRUITING

    Sakai, Osaka, 590-0197, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • Niigata Cancer Center Hospital

    RECRUITING

    Niigata, 951-8566, Japan

  • Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong

  • Show Chwan Memorial Hospital

    RECRUITING

    Changhua, 500, Taiwan

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER